Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN12 | Q05209 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13082002 | 0.90 | KMT2A (0.51) | PTPN12PTPN22KMT2AMEN1POLB | |
| SCHEMBL13855614 | 0.81 | CISD1 (0.44) | POLBMAPT | |
| SCHEMBL8337812 | 0.77 | PTPN12 (0.43) | PTPN12PTPN22KMT2AKDM4EMEN1 | |
| SCHEMBL13081954 | 0.75 | PLG (0.49) | KMT2AMEN1POLBMAPT | |
| SCHEMBL8334697 | 0.72 | KMT2A (0.53) | PTPN12PTPN22KMT2AKDM4EMEN1 | |
| SCHEMBL8594082 | 0.71 | MAP3K5 (0.78) | PTPN22MAPT | |
| SCHEMBL13056331 | 0.71 | MAP3K5 (0.78) | PTPN22MAPT | |
| SCHEMBL8594085 | 0.71 | MAP3K5 (0.78) | PTPN22MAPT | |
| SCHEMBL10507869 | 0.71 | PTPN12 (0.53) | PTPN12PTPN22PTPN1KMT2AMEN1 | |
| SCHEMBL1906469 | 0.70 | PTPN1 (0.56) | PTPN12PTPN22PTPN1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | APAF1, ANTXR2, SERPINB1 | PTPN12 3273/4885PTPN22 3261/4885PTPN1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.